One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1093/annonc/mdz446.018
Copy DOI Journal: Annals of Oncology |  Publication Date: Nov 1, 2019 |
 Citations: 11 |  License type: elsevier-specific: oa user license |
Affiliation: Hospital Universitario Virgen del Rocío, Pfizer (United States), Guangdong Provincial People's Hospital, National Cancer Center Hospital East, Institut Català d'Ornitologia, Institut Català d'Oncologia, Chungbuk National University, Southwest Hospital, Kindai University Hospital, The Maria Sklodowska-Curie National Research Institute of OncologyLBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
